Repare Therapeutics | 8-K: FY2025 Q2 Revenue: USD 250 K

LB filings
2025.08.08 11:11
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q2, the actual value is USD 250 K.

EPS: As of FY2025 Q2, the actual value is USD -0.39, beating the estimate of USD -0.56.

Financial Data and Outlook Summary

Cash, Cash Equivalents, and Marketable Securities

  • As of June 30, 2025: $109.5 million.

Revenue from Collaboration Agreements

  • Three months ended June 30, 2025: $0.3 million.
  • Six months ended June 30, 2025: $0.3 million.
  • Three months ended June 30, 2024: $1.1 million.
  • Six months ended June 30, 2024: $53.5 million.

Research and Development Expense (Net of Tax Credits)

  • Three months ended June 30, 2025: $14.3 million.
  • Six months ended June 30, 2025: $34.6 million.
  • Three months ended June 30, 2024: $30.1 million.
  • Six months ended June 30, 2024: $63.1 million.

General and Administrative Expenses

  • Three months ended June 30, 2025: $6.0 million.
  • Six months ended June 30, 2025: $13.7 million.
  • Three months ended June 30, 2024: $8.3 million.
  • Six months ended June 30, 2024: $16.9 million.

Net Loss

  • Three months ended June 30, 2025: $16.7 million, or $0.39 per share.
  • Six months ended June 30, 2025: $46.8 million, or $1.09 per share.
  • Three months ended June 30, 2024: $34.8 million, or $0.82 per share.
  • Six months ended June 30, 2024: $21.6 million, or $0.51 per share.

Outlook / Guidance

  • Repare Therapeutics expects to deliver initial data from the LIONS and POLAR trials in the fourth quarter of 2025.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.